Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective α1-adrenoceptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urinary flow. It is highly selective for α1A receptors, resulting in minimal effect on blood pressure compared to non-selective alpha-blockers.
## Primary Indications
* Benign Prostatic Hyperplasia (BPH) - treatment of signs and symptoms.
* Off-label: Ureteral stone expulsion therapy (facilitating passage of distal stones).
## Adult Dosing
* **BPH:** 0.4 mg orally once daily, taken 30 minutes after the same meal each day.
* **Max dose:** 0.8 mg daily if no response after 2–4 weeks at 0.4 mg.
* **Ureteral Stones (Off-label):** 0.4 mg once daily for up to 4 weeks.
## Pediatric Dosing
**Not indicated for pediatric use.** Tamsulosin is generally not used in children. Rare off-label use for pediatric bladder dysfunction may occur in specialized centers, but there is no standardized dosing or established pediatric safety profile.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment necessary; however, use with caution in severe renal impairment (CrCl <10 mL/min).
* **Hepatic Impairment:** No dosage adjustment in mild-to-moderate impairment. Avoid in severe hepatic impairment (Child-Pugh Class C).
## Contraindications
* Known hypersensitivity to tamsulosin or any component of the formulation.
## Adverse Effects
* **Most Common:** Dizziness, headache, abnormal ejaculation (retrograde or decreased volume).
* **Cardiovascular:** Orthostatic hypotension (risk is lower than non-selective alpha-blockers but remains).
* **Ocular:** Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery.
* **Other:** Rhinitis, fatigue, nausea, diarrhea.
## Key Drug Interactions
* **Strong CYP3A4/2D6 Inhibitors:** (e.g., ketoconazole, fluoxetine, paroxetine) May significantly increase tamsulosin plasma concentrations; avoid or reduce tamsulosin dose.
* **PDE-5 Inhibitors:** (e.g., sildenafil, tadalafil) Concurrent use may lead to symptomatic hypotension.
* **Other Antihypertensives:** Potential for additive blood pressure lowering.
## Monitoring
* Baseline and periodic blood pressure (for orthostasis).
* Assess symptom improvement (e.g., AUA Symptom Score) within 2–4 weeks.
* Monitor for signs of IFIS if the patient is scheduled for cataract surgery.
## Clinical Pearls
* **Administration:** Always instruct the patient to take the medication 30 minutes after the *same* meal daily to ensure consistent bioavailability.
* **Cataract Surgery:** Patients should inform their ophthalmologist of current or past tamsulosin use, as it significantly increases the risk of IFIS complications.
* **Hypotension:** Counsel patients on the risk of dizziness or syncope, especially when rising from a sitting or lying position shortly after dosing.
***
*Disclaimer: This information is for educational purposes only. Clinical guidelines and local protocols vary significantly. Always verify doses, contraindications, and drug interactions using current, institutional-approved drug references (e.g., Lexicomp, Micromedex, or the BNF) before prescribing or administering medication.*
